ArticleProceedings of the South Dakota Academy of Science2008
OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES.
Article in Proceedings of the South Dakota Academy of Science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Birth of MTH1 as a therapeutic target for glioblastoma: MTH1 is indispensable for gliomatumorigenesis.American journal of translational research · 2016Article
- Suicide Gene Therapy for Cancer - Current Strategies.Journal of genetic syndromes & gene therapy · 2013Article
- Eradication of Human Ovarian Cancer Cells by Transgenic Expression of RecombinantJournal of genetic syndromes & gene therapy · 2013Article
- Frontiers in Suicide Gene Therapy of Cancer.Journal of genetic syndromes & gene therapy · 2012Article
- Routing of Biomolecules and Transgenes' Vectors in Nuclei of Oocytes.Journal of fertilization in vitro · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Ovarian cancer is the leading cause of death among all gynecological cancers. Some women choose bilateral oophorectomy as means of cancer prevention. In most patients, by the time this cancer is diagnosed, it has already metastasized. Treatment involves oophorectomy followed by radiation, chemo-, and immuno-therapies. However, oopherectomy results in infertility and fails to eliminate all cancer cells. Radiation and chemotherapy cause severe side effects and may lead to genetic mutations in DNA of the ova.The ultimate goal of this project is development of a therapy which would target a therapeutic gene specific to ovarian cancer cells causing their apoptosis, but which would leave ova and other cells unharmed.Herein, we report the proof of concept for such a therapy, in which genetically engineered single chain variable fragment (scFv) antibodies against HER2/ neu, RON, and NK1R, guide the delivery of the therapeutic transgenes into the cancer cells of the ovaries. Under ovary specific promoters (OSP), the transgene expression generates the intracellular scFv antibodies, which quench cell antioxidative enzymes, thus raising levels of reactive oxygen species (ROS), inflicting oxidative stress, activating apoptotic signaling pathways, and causing cancer cell deaths.
Identifiers
23243327PMC3520127W2115851073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.